B. Riley Has Positive Forecast for biote FY2025 Earnings

biote Corp. (NASDAQ:BTMD) – Research analysts at B. Riley boosted their FY2025 earnings per share estimates for shares of biote in a report released on Thursday, November 6th. B. Riley analyst J. Van. Sinderen now anticipates that the company will post earnings of $0.38 per share for the year, up from their previous forecast of $0.25. B. Riley currently has a “Neutral” rating on the stock. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q4 2025 earnings at ($0.04) EPS, FY2026 earnings at $0.15 EPS and FY2027 earnings at $0.28 EPS.

biote (NASDAQ:BTMD) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.17. The firm had revenue of $47.96 million for the quarter, compared to the consensus estimate of $47.76 million. biote had a negative return on equity of 21.00% and a net margin of 15.73%. biote has set its FY 2025 guidance at EPS.

BTMD has been the subject of a number of other research reports. Weiss Ratings lowered shares of biote from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Wall Street Zen lowered shares of biote from a “buy” rating to a “hold” rating in a report on Sunday, November 2nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.00.

biote Stock Up 6.1%

Shares of BTMD opened at $2.61 on Monday. biote has a 52-week low of $2.43 and a 52-week high of $6.98. The company has a market capitalization of $129.04 million, a PE ratio of 2.90 and a beta of 1.15. The stock has a fifty day simple moving average of $3.02 and a two-hundred day simple moving average of $3.50.

Institutional Trading of biote

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its position in shares of biote by 15.0% during the first quarter. Acadian Asset Management LLC now owns 700,871 shares of the company’s stock worth $2,330,000 after buying an additional 91,672 shares during the period. Strs Ohio purchased a new stake in shares of biote in the 1st quarter valued at $312,000. Nuveen LLC acquired a new position in biote during the 1st quarter worth about $872,000. Trexquant Investment LP boosted its holdings in biote by 18.5% during the 1st quarter. Trexquant Investment LP now owns 120,544 shares of the company’s stock valued at $401,000 after acquiring an additional 18,787 shares during the period. Finally, Virtu Financial LLC purchased a new position in biote during the 1st quarter valued at about $62,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.